IntelGenx Technologies Corp. announced various initiatives aimed at helping the Company address, and satisfactorily respond to, the Complete Response Letter ("CRL") that it recently received from the U.S. Food and Drug Administration (FDA) regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT VersaFilm, as well as maintain IntelGenx's financial stability in light of the current market environment and the challenges posed by the global COVID-19 pandemic. Pursuant to IntelGenx's revised business strategy, effective immediately, all product development and manufacturing functions, including R&D, regulatory affairs and operations, will be led by Dr. Horst G. Zerbe, CEO of the IntelGenx, while Mr. Andre Godin, IntelGenx's President and Chief Financial Officer will have overall responsibility for all business functions, including finance and business development. In addition, the Company's Board and management will immediately conduct a comprehensive review of all functions and reporting relationships in order to determine what, if any, management structural and personnel changes or additions are necessary to help ensure the Company's future success in these new circumstances.